935PDPreliminary safety, efficacy, and PK/PD...

Annals of Oncology 2018 / 10 Vol. 29; Iss. suppl_8

935PDPreliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer

Oaknin, A, Ellard, S L, Leath III, C, Moreno, V, Kristeleit, R, Guo, W, Lu, S, Jenkins, D, McEachern, K, Yu Jen, K, Dunlap, S, Im, E, Gilbert, L
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy285.144
Date:
October, 2018
File:
PDF, 78 KB
english, 2018
Conversion to is in progress
Conversion to is failed